Three West Coast healthcare venture capital firms – Canaan Partners, Vivo Capital and Frazier Healthcare – are teaming up to launch a stealth new startup called Nexcida Therapeutics. It’s focused on infectious disease therapeutics, CEO David Socks said in an email.
The startup was launched by Frazier Healthcare, which also led the Series A, with Vivo and Canaan investing as well. Socks is an alum from Cadence Pharmaceuticals and Incline Therapeutics, is the startup’s CEO.
It’s raised $2.75 million of a proposed $21.3 million round, according to a regulatory filing. Nexcida is in its nascence and under the radar – it has no website.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Canaan and Frazier Healthcare are your typical life sciences VCs; Vivo Capital, however, focuses on building companies both stateside and in China.
Photo: Flickr user Fun Flying